{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:05:20Z","timestamp":1774015520725,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["73531"],"award-info":[{"award-number":["73531"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tice.2026.103390","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:43:26Z","timestamp":1770828206000},"page":"103390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["p16 positivity as a potent indicator of high-grade histology and its interplay with HER2\/neu in urothelial bladder carcinoma"],"prefix":"10.1016","volume":"100","author":[{"given":"Hanieh","family":"Kolahi Azar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-570X","authenticated-orcid":false,"given":"Nima","family":"Beheshtizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tala","family":"Pourlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.tice.2026.103390_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12032-022-01817-6","article-title":"The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review","volume":"39","author":"Asgari-Karchekani","year":"2022","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.tice.2026.103390_bib2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3892\/etm.2022.11640","article-title":"Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: a retrospective single\u2011center experience","volume":"24","author":"Bai","year":"2022","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.tice.2026.103390_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12253-008-9027-y","article-title":"No strong association between HER-2\/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas","volume":"14","author":"Caner","year":"2008","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cells11061033","article-title":"On the cutting edge of oral cancer prevention: finding risk-predictive markers in precancerous lesions by longitudinal studies","volume":"11","author":"Crawford","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.tice.2026.103390_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241775","article-title":"Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO\/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy","volume":"15","author":"Crespo","year":"2020","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","article-title":"Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.tice.2026.103390_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116312","article-title":"Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer","volume":"173","author":"Fan","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.tice.2026.103390_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tice.2026.103390_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653491","article-title":"The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis","volume":"11","author":"Gan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tice.2026.103390_bib10","series-title":"Management of Muscle Invasive Bladder Cancer","author":"Goonewardene","year":"2021"},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib11","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2014.42","article-title":"Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review","volume":"110","author":"Gr\u00f8nh\u00f8j Larsen","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tice.2026.103390_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42047-019-0030-2","article-title":"Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma","volume":"2","author":"Hashmi","year":"2019","journal-title":"Surg. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bju.16100","article-title":"Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications","volume":"132","author":"Jahnson","year":"2023","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.tice.2026.103390_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/atm-23-1465","article-title":"Narrative review on the evolving role of HER2\/neu targeting in uterine serous cancers","volume":"12","author":"Jayraj","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"21","key":"10.1016\/j.tice.2026.103390_bib17","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","article-title":"HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells","volume":"22","author":"Knuefermann","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.tice.2026.103390_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2824","article-title":"Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers","volume":"13","author":"Lamy","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"25","key":"10.1016\/j.tice.2026.103390_bib19","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1021\/bi200642e","article-title":"Regulatory mechanisms of tumor suppressor P16INK4A and their relevance to cancer","volume":"50","author":"Li","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.tice.2026.103390_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.747194","article-title":"Integrating molecular biomarker inputs into development and use of clinical cancer therapeutics","volume":"12","author":"Louie","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"26","key":"10.1016\/j.tice.2026.103390_bib21","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3748\/wjg.v24.i26.2818","article-title":"Biomarkers of gastric cancer: current topics and future perspective","volume":"24","author":"Matsuoka","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/PAP.0000000000000458","article-title":"The role of predictive and prognostic biomarkers in lower female genital tract pathology: PD-L1, MMR, HER2, p16, p53, and beyond","volume":"32","author":"Mills","year":"2025","journal-title":"Adv. Anat. Pathol."},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2026.103390_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.875188","article-title":"An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer","volume":"12","author":"Nisar","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.tice.2026.103390_bib26","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/cancers16183145","article-title":"Prognostic and predictive roles of HER2 status in non-breast and non-gastroesophageal carcinomas","volume":"16","author":"Quaquarini","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.tice.2026.103390_bib27","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2026.103390_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tice.2026.103390_bib29","article-title":"Investigating the effect of ribosomal-stress induced senescence on basal-like breast cancer","author":"Sullivan","year":"2025","journal-title":"Queen Mary Univ. Lond."},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch."},{"issue":"17","key":"10.1016\/j.tice.2026.103390_bib31","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/1078-0432.CCR-24-3912","article-title":"ERBB2\/HER2 Alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer","volume":"31","author":"Vandekerkhove","year":"2025","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.tice.2026.103390_bib32","article-title":"The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.tice.2026.103390_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4161\/cc.23883","article-title":"CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity","volume":"12","author":"Zhao","year":"2013","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.tice.2026.103390_bib34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3892\/etm.2021.10491","article-title":"Effects of the p16\/cyclin D1\/CDK4\/Rb\/E2F1 pathway on aberrant lung fibroblast proliferation in neonatal rats exposed to hyperoxia","volume":"22","author":"Zhao","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.tice.2026.103390_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ultrasmedbio.2025.09.013","article-title":"Prediction of HER2 expression in urothelial carcinoma of the bladder: are ultrasound-based radiomic features significant?","volume":"52","author":"Zhuang","year":"2026","journal-title":"Ultrasound Med. Biol."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626000820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626000820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:56:45Z","timestamp":1774007805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816626000820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S0040816626000820"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2026.103390","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p16 positivity as a potent indicator of high-grade histology and its interplay with HER2\/neu in urothelial bladder carcinoma","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2026.103390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103390"}}